Business
IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors
- First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, in Amgen-sponsored
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"- First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, in Amgen-sponsored Phase 1/2 clinical trial\n- Global clinical trial will evaluate IDE397 and AMG 193 combination as potential first-in-class synthetic lethality combination in MTAP-deletion patients with planned expansion in NSCLC\n- Earlier reported unconfirmed partial response for IDE397 monotherapy has confirmed with -47% tumor shrinkage by RECIST 1.1 in a high-priority MTAP-deletion solid tumor type\nSOUTH SAN FRANCISCO, Calif., Aug. 2, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced achievement of First-Patient-In for the Amgen-sponsored Phase 1/2 clinical trial evaluating the combination of IDE397, the IDEAYA investigational MAT2A inhibitor, and AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having tumors with MTAP deletion, with an expansion focus in NSCLC.\n\n \n \n \n \n \n \n\n \n\"We are excited to pursue this potential first-in-class synthetic lethality combination therapy targeting mechanistically complementary nodes of the MTAP methylation pathway – MAT2A and PRMT5. The clinical strategy is supported by preliminary signals of monotherapy activity and by compelling preclinical efficacy, tolerability and selectivity for the combination,\" said Dr. Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.\nIDE397 is IDEAYA's potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A). IDEAYA observed clinical efficacy for IDE397 as monotherapy in multiple MTAP-deletion high-priority tumor types based on its experience across several patients in early dose expansion, including an earlier-reported unconfirmed partial response which has confirmed by RECIST 1.1 (~47% tumor reduction). \nAMG 193 is the Amgen investigational methylthioadenosine- (MTA-) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. \nIDEAYA and Amgen are collaborating to clinically evaluate the IDE397 and AMG 193 combination in patients having tumors with MTAP deletion in an Amgen-sponsored clinical trial pursuant to a Clinical Trial Collaboration and Supply Agreement, or CTCSA. The glob...